Veracyte Inc. (NASDAQ:VCYT) shares traded down 1% during mid-day trading on Friday . The stock traded as low as $4.85 and last traded at $4.99, with a volume of 70,804 shares. The stock had previously closed at $5.04.

Several research analysts have issued reports on the stock. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Veracyte in a report on Monday, June 13th. Leerink Swann reiterated a “buy” rating and set a $8.00 target price (down from $11.00) on shares of Veracyte in a report on Friday, March 11th. Cantor Fitzgerald reiterated a “buy” rating on shares of Veracyte in a report on Monday, June 13th. Finally, Zacks Investment Research cut shares of Veracyte from a “buy” rating to a “hold” rating in a report on Friday, March 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $9.75.

The company’s 50-day moving average is $5.22 and its 200 day moving average is $5.69. The company’s market capitalization is $139.01 million.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01. During the same quarter in the prior year, the business posted ($0.34) EPS. The company had revenue of $13.55 million for the quarter, compared to analysts’ expectations of $13.08 million. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. On average, equities research analysts anticipate that Veracyte Inc. will post ($1.31) earnings per share for the current fiscal year.

In other Veracyte news, CEO Bonnie H. Anderson purchased 5,000 shares of the business’s stock in a transaction on Friday, June 3rd. The shares were bought at an average cost of $5.40 per share, for a total transaction of $27,000.00. Following the completion of the purchase, the chief executive officer now directly owns 7,500 shares of the company’s stock, valued at $40,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Veracyte, Inc is a molecular diagnostics company. The Company is engaged in the field of molecular cytology providing genomic solutions to resolve diagnostic ambiguity and enable physicians to make treatment decisions at an early stage in patient care. It targets diseases in which a large number of patients undergo invasive diagnostic procedures that could be avoided with a diagnosis from a cytology sample.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.